AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31492651 — intervention group
Group type: COMPARATOR
Intervention: interferon beta-1a
Number of subjects: 1346
Study 28987625 — intervention group
Group type: EXPERIMENTAL
Intervention: 8% arginine‐containing toothpaste
Number of subjects: 12
Study 28987625 — intervention group
Group type: COMPARATOR
Intervention: Arginine-free toothpaste (control)
Number of subjects: 12
Study 25880207 — intervention group
Group type: EXPERIMENTAL
Intervention: Ripasudil, 0.4% combined with Timolol, 0.5%
Number of subjects: 413
Study 25880207 — intervention group
Group type: EXPERIMENTAL
Intervention: Ripasudil, 0.4% combined with Latanoprost, 0.005%
Number of subjects: 413
Study 23840043 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-1 PENNVAX®-B DNA vaccine (PV) plus interleukin 12 (IL-12) with electroporation
Number of subjects: 0
Study 23840043 — intervention group
Group type: COMPARATOR
Intervention: HIV-1 PENNVAX®-B DNA vaccine (PV) plus interleukin 12 (IL-12) without electroporation
Number of subjects: 0
Study 21612471 — intervention group
Group type: EXPERIMENTAL
Intervention: Early locomotor training (treadmill with body-weight support, started 2 months after stroke)
Number of subjects: 408
Study 21612471 — intervention group
Group type: EXPERIMENTAL
Intervention: Late locomotor training (treadmill with body-weight support, started 6 months after stroke)
Number of subjects: 408
Study 21612471 — intervention group
Group type: COMPARATOR
Intervention: Home-exercise program (managed by a physical therapist, started 2 months after stroke)
Number of subjects: 408
Study 21612471 — intervention group
Group type: EXPERIMENTAL
Intervention: Early locomotor training
Number of subjects: 408
Study 21612471 — intervention group
Group type: EXPERIMENTAL
Intervention: Late locomotor training
Number of subjects: 408
Study 19349671 — intervention group
Group type: EXPERIMENTAL
Intervention: Short 7-day GnRHa protocol
Number of subjects: 88
Study 19349671 — intervention group
Group type: COMPARATOR
Intervention: GnRHa long protocol
Number of subjects: 88
Study 19349671 — intervention group
Group type: EXPERIMENTAL
Intervention: Both protocols
Number of subjects: 88
Study 16885576 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy (NRT)
Number of subjects: 4792
Study 16885576 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4792
Study 15670429 — intervention group
Group type: EXPERIMENTAL
Intervention: Little by Little CD-ROM with reminder calls
Number of subjects: 481
Study 15670429 — intervention group
Group type: EXPERIMENTAL
Intervention: Little by Little CD-ROM without reminder calls
Number of subjects: 481
Study 15670429 — intervention group
Group type: COMPARATOR
Intervention: Stress management CD-ROM (control condition)
Number of subjects: 481
Study 11414674 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity aerobic training (HI)
Number of subjects: 503
Study 11414674 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 503
Study 9225876 — intervention group
Group type: EXPERIMENTAL
Intervention: S-adenosyl-L-methionine (SAMe) 600 mg i.v. daily for 10 days
Number of subjects: 34
Study 9225876 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 8488368 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetorphan
Number of subjects: 69
Study 8488368 — intervention group
Group type: COMPARATOR
Intervention: Loperamide
Number of subjects: 69
Study 3624669 — intervention group
Group type: EXPERIMENTAL
Intervention: Active pyridostigmine (180 mg orally every 12 hours)
Number of subjects: 20
Study 3624669 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 3624669 — intervention group
Group type: EXPERIMENTAL
Intervention: Active pyridostigmine
Number of subjects: 20
Study 29251296 — intervention group
Group type: EXPERIMENTAL
Intervention: Distress Thermometer and Problem List with nurse‐guided follow‐up (n=53)
Number of subjects: 110
Study 29251296 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n=57)
Number of subjects: 110
Study 27565304 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychologically-informed physiotherapy
Number of subjects: 138
Study 27565304 — intervention group
Group type: COMPARATOR
Intervention: Current best care
Number of subjects: 138
Study 25429523 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced visual acuity (VA) measured using a retroilluminated logMAR chart with tumbling‐E optotypes.
Number of subjects: 725423
Study 25429523 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender comparison
Number of subjects: 725423
Study 25429523 — intervention group
Group type: EXPERIMENTAL
Intervention: Urban vs rural comparison
Number of subjects: 725423
Study 25429523 — intervention group
Group type: EXPERIMENTAL
Intervention: Projected cases of reduced VA
Number of subjects: 725423
Study 25429523 — intervention group
Group type: EXPERIMENTAL
Intervention: Population density correlation
Number of subjects: 725423
Study 23532240 — intervention group
Group type: EXPERIMENTAL
Intervention: EDTA chelation (3 g of disodium EDTA, 7 g of ascorbate, B vitamins, electrolytes, procaine, and heparin) administered via 40 infusions of a 500-mL solution over 30 weeks (weekly for 30 weeks, then 10 infusions 2 to 8 weeks apart)
Number of subjects: 1708
Study 23532240 — intervention group
Group type: COMPARATOR
Intervention: Placebo (500-mL solution) administered in the same regimen as the EDTA group
Number of subjects: 1708
Study 23532240 — intervention group
Group type: EXPERIMENTAL
Intervention: EDTA chelation
Number of subjects: 1708
Study 23532240 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1708
Study 20135607 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical Trial Unit for Orthopaedics and Trauma Surgery
Number of subjects: 0
Study 20135607 — intervention group
Group type: EXPERIMENTAL
Intervention: Training of supporting physicians through rotations in CHIR-Net
Number of subjects: 0
Study 18761646 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (MET), n = 15, dose: 1500 mg daily
Number of subjects: 28
Study 18761646 — intervention group
Group type: COMPARATOR
Intervention: Placebo, n = 13
Number of subjects: 28
Study 17405254 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination IGF‐I/GH therapy
Number of subjects: 97
Study 17405254 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment (normal saline solution)
Number of subjects: 97
Study 14527528 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative fear information
Number of subjects: 0
Study 14527528 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive fear information
Number of subjects: 0
Study 10767775 — intervention group
Group type: EXPERIMENTAL
Intervention: Denacen (test formulation)
Number of subjects: 24
Study 10767775 — intervention group
Group type: COMPARATOR
Intervention: Calcort (reference formulation)
Number of subjects: 24
Study 8665378 — intervention group
Group type: EXPERIMENTAL
Intervention: Permethrin impregnated bednets
Number of subjects: 48
Study 1678757 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone injection pen
Number of subjects: 20
Study 1678757 — intervention group
Group type: COMPARATOR
Intervention: Conventional syringe method
Number of subjects: 20
Study 6311000 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefamandole plus amdinocillin
Number of subjects: 50
Study 6311000 — intervention group
Group type: COMPARATOR
Intervention: Cefamandole
Number of subjects: 50
Study 11772821 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil (0.5% end‐tidal isoflurane, remifentanil up to 2 microg x kg(‐1) x min(‐1))
Number of subjects: 43
Study 11772821 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane (60% nitrous oxide, isoflurane up to 2% end‐tidal)
Number of subjects: 43
Study 30171664 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate intensive treatment (eyedrops containing drugs from three different classes combined with 360° laser trabeculoplasty)
Number of subjects: 242
Study 30171664 — intervention group
Group type: COMPARATOR
Intervention: Commonly recommended stepped regimen (drug monotherapy in accordance with common glaucoma guidelines)
Number of subjects: 242
Study 26823927 — intervention group
Group type: EXPERIMENTAL
Intervention: Care Plan
Number of subjects: 40
Study 26823927 — intervention group
Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 40
Study 24300226 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-bedding group (cared for continuously in the same incubator or crib)
Number of subjects: 134
Study 24300226 — intervention group
Group type: COMPARATOR
Intervention: Standard care group (cared for in a separate incubator or crib)
Number of subjects: 134
Study 24300226 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-bedding group
Number of subjects: 134
Study 24300226 — intervention group
Group type: COMPARATOR
Intervention: Standard care group
Number of subjects: 134
Study 22552037 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA-enriched fish oil (800 mg/d)
Number of subjects: 2399
Study 22552037 — intervention group
Group type: COMPARATOR
Intervention: Vegetable oil capsules without DHA
Number of subjects: 2399
Study 20175903 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment by letter on NHS headed note paper from General Practices
Number of subjects: 217
Study 20175903 — intervention group
Group type: COMPARATOR
Intervention: Other recruitment methods (not specified)
Number of subjects: 217
Study 20175903 — intervention group
Group type: COMPARATOR
Intervention: GP letters
Number of subjects: 217
Study 18418808 — intervention group
Group type: EXPERIMENTAL
Intervention: High-volume training (HVT)
Number of subjects: 10
Study 18418808 — intervention group
Group type: COMPARATOR
Intervention: Low-volume, high-intensity training (HIT)
Number of subjects: 10
Study 18418808 — intervention group
Group type: EXPERIMENTAL
Intervention: Taper period after both training types
Number of subjects: 10
Study 18418808 — intervention group
Group type: EXPERIMENTAL
Intervention: Both training periods
Number of subjects: 10
Study 15690862 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide/oxygen
Number of subjects: 7
Study 15690862 — intervention group
Group type: COMPARATOR
Intervention: Placebo air/oxygen mixture
Number of subjects: 7
Study 12394990 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative customized exercise program
Number of subjects: 28
Study 12394990 — intervention group
Group type: COMPARATOR
Intervention: Routine perioperative care (Control)
Number of subjects: 28
Study 10457270 — intervention group
Group type: COMPARATOR
Intervention: FokI polymorphism (ff genotype)
Number of subjects: 400
Study 10457270 — intervention group
Group type: EXPERIMENTAL
Intervention: FokI polymorphism (Ff and FF genotypes)
Number of subjects: 400
Study 10457270 — intervention group
Group type: EXPERIMENTAL
Intervention: FokI polymorphism
Number of subjects: 400
Study 7607377 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic abdominal Burch colposuspension (via laparoscopy and 'retziusscopy')
Number of subjects: 20
Study 2389061 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled release vaginal polymer pessary containing 10 mg prostaglandin E2 (PGE2), designed to release 0.6 mg per hour in vivo
Number of subjects: 25
Study 2389061 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro release profile of PGE2 from the polymer pessary
Number of subjects: 25
Study 1015181 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous heparin (5,000 U) administered 2 hours before surgery and every 8 hours for 6 days
Number of subjects: 99
Study 1015181 — intervention group
Group type: COMPARATOR
Intervention: Control group (no heparin treatment)
Number of subjects: 99
Study 30593689 — intervention group
Group type: EXPERIMENTAL
Intervention: BRP0.5: basal diet + 0.25 g BPO + 0.25 g RPO/kg diet
Number of subjects: 100
Study 30593689 — intervention group
Group type: EXPERIMENTAL
Intervention: BRP1.0: basal diet + 0.50 g BPO + 0.50 g RPO/kg diet
Number of subjects: 100
Study 30593689 — intervention group
Group type: EXPERIMENTAL
Intervention: BRP1.5: basal diet + 0.75 g BPO + 0.75 g RPO/kg diet
Number of subjects: 100
Study 30593689 — intervention group
Group type: EXPERIMENTAL
Intervention: BRP mixture
Number of subjects: 100
Study 30593689 — intervention group
Group type: COMPARATOR
Intervention: Control: basal diet
Number of subjects: 100
Study 30593689 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 100
Study 25224814 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy (CRT) with weekly cisplatin (30 mg/m²) and the same RT dose (66-70 Gy/2 Gy fraction/5 fractions weekly)
Number of subjects: 186
Study 25224814 — intervention group
Group type: COMPARATOR
Intervention: Conventional radiotherapy (RT) (66-70 Gy/2 Gy fraction/5 fractions weekly)
Number of subjects: 186
Study 25224814 — intervention group
Group type: COMPARATOR
Intervention: Accelerated radiotherapy (RT) (66-70 Gy/2 Gy fraction/6 fractions weekly)
Number of subjects: 186
Study 24484450 — intervention group
Group type: EXPERIMENTAL
Intervention: Salovum® (16 grams initially, followed by 8 g every 5 hours until recovery)
Number of subjects: 36
Study 24484450 — intervention group
Group type: COMPARATOR
Intervention: Placebo (ordinary egg yolk mixed in oral rehydration salts)
Number of subjects: 36
Study 22357783 — intervention group
Group type: EXPERIMENTAL
Intervention: Revised pain protocol (RP group)
Number of subjects: 1728
Study 22357783 — intervention group
Group type: COMPARATOR
Intervention: Control group (Ctrl group)
Number of subjects: 1728
Study 20840339 — intervention group
Group type: EXPERIMENTAL
Intervention: Prothrombin Complex Concentrate (PCC)
Number of subjects: 40
Study 20840339 — intervention group
Group type: COMPARATOR
Intervention: Fresh Frozen Plasma (FFP)
Number of subjects: 40
Study 18580416 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise
Number of subjects: 202
Study 18580416 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exercise
Number of subjects: 202
Study 18580416 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 202
Study 18580416 — intervention group
Group type: COMPARATOR
Intervention: Placebo pill
Number of subjects: 202
Study 15728052 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacteriostatic saline (benzyl alcohol) as a preinjection
Number of subjects: 120
Study 15728052 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine mixed with propofol
Number of subjects: 120
Study 15728052 — intervention group
Group type: COMPARATOR
Intervention: Placebo (no bacteriostatic saline or lidocaine)
Number of subjects: 120
Study 12966253 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment (not specified in the abstract)
Number of subjects: 61
Study 10823399 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patch
Number of subjects: 504
Study 10823399 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine gum
Number of subjects: 504
Study 10823399 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine spray
Number of subjects: 504
Study 10823399 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine inhaler
Number of subjects: 504
Study 10823399 — intervention group
Group type: EXPERIMENTAL
Intervention: Continued use of NRT at week 15
Number of subjects: 504
Study 2049554 — intervention group
Group type: EXPERIMENTAL
Intervention: MTX + CSA
Number of subjects: 40
Study 2049554 — intervention group
Group type: COMPARATOR
Intervention: MTX
Number of subjects: 40
Study 2049554 — intervention group
Group type: COMPARATOR
Intervention: CSA
Number of subjects: 40
Study 6404596 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose combined oral contraceptive (ethinyl estradiol 0.03 mg and levonorgestrel 0.15 mg)
Number of subjects: 0
Study 6404596 — intervention group
Group type: COMPARATOR
Intervention: Injectable placebo
Number of subjects: 0
Study 6404596 — intervention group
Group type: COMPARATOR
Intervention: Copper T
Number of subjects: 0
Study 30610027 — intervention group
Group type: EXPERIMENTAL
Intervention: Online, remotely delivered, therapist-supported exposure response prevention behavioural therapy for tics
Number of subjects: 0
Study 30610027 — intervention group
Group type: COMPARATOR
Intervention: Online, remotely delivered, therapist-supported education about tics and co-occurring conditions
Number of subjects: 0
Study 29911663 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational program (talk, video projection, informative leaflets, narrative short stories, role-play activities)
Number of subjects: 970
Study 27220840 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan/Amlodipine (OLM/AML) 20-40mg/5-10mg
Number of subjects: 88
Study 27220840 — intervention group
Group type: COMPARATOR
Intervention: Perindopril/Amlodipine (PER/AML) 4-8mg/5-10mg
Number of subjects: 88
Study 27220840 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan/Amlodipine (OLM/AML)
Number of subjects: 88
Study 27220840 — intervention group
Group type: COMPARATOR
Intervention: Perindopril/Amlodipine (PER/AML)
Number of subjects: 88
Study 24577854 — intervention group
Group type: EXPERIMENTAL
Intervention: Futsal (FUT)
Number of subjects: 20
Study 24577854 — intervention group
Group type: COMPARATOR
Intervention: Moderate-intensity continuous exercise (MOD)
Number of subjects: 20
Study 24577854 — intervention group
Group type: EXPERIMENTAL
Intervention: Both FUT and MOD
Number of subjects: 20
Study 22732225 — intervention group
Group type: EXPERIMENTAL
Intervention: Career academy attendance (full enrollment)
Number of subjects: 1306
Study 22732225 — intervention group
Group type: EXPERIMENTAL
Intervention: Career academy attendance (partial enrollment)
Number of subjects: 1306
Study 22732225 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 1306
Study 20437287 — intervention group
Group type: EXPERIMENTAL
Intervention: Education session on drug-to-drug interactions
Number of subjects: 82
Study 20437287 — intervention group
Group type: COMPARATOR
Intervention: Control group (no education session)
Number of subjects: 82
Study 16889999 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis with analgesia suggestions
Number of subjects: 45
Study 16889999 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis with relaxation suggestions
Number of subjects: 45
Study 16889999 — intervention group
Group type: COMPARATOR
Intervention: Relaxation
Number of subjects: 45
Study 15767219 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole 200 mg/day with telithromycin 800 mg/day
Number of subjects: 34
Study 15767219 — intervention group
Group type: EXPERIMENTAL
Intervention: Grapefruit juice (single-dose) with telithromycin 800 mg/day
Number of subjects: 34
Study 12504970 — intervention group
Group type: EXPERIMENTAL
Intervention: Active management with oral misoprostol (50 microg every 4 hours, max 5 doses)
Number of subjects: 61
Study 12504970 — intervention group
Group type: EXPERIMENTAL
Intervention: Active management with oral misoprostol
Number of subjects: 61
Study 12504970 — intervention group
Group type: COMPARATOR
Intervention: Conservative management (induction with PGE(2) gel or oxytocin after 24 hours)
Number of subjects: 61
Study 12504970 — intervention group
Group type: COMPARATOR
Intervention: Conservative management
Number of subjects: 61
Study 9803051 — intervention group
Group type: EXPERIMENTAL
Intervention: Ayurvedic formulation (Misrakasneham)
Number of subjects: 0
Study 9803051 — intervention group
Group type: COMPARATOR
Intervention: Conventional laxative tablet (Sofsena)
Number of subjects: 0
Study 8613310 — intervention group
Group type: EXPERIMENTAL
Intervention: Furazolidone treatment
Number of subjects: 21
Study 1956988 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 18
Study 1956988 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 18
Study 1956988 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 6971716 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary bypass surgery
Number of subjects: 508
Study 6971716 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment
Number of subjects: 508
Study 31535143 — intervention group
Group type: EXPERIMENTAL
Intervention: V160 vaccine
Number of subjects: 0
Study 31535143 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28652196 — intervention group
Group type: EXPERIMENTAL
Intervention: E.BMP‐2 with an HA carrier
Number of subjects: 93
Study 28652196 — intervention group
Group type: COMPARATOR
Intervention: Autogenous iliac bone graft (AIBG)
Number of subjects: 93
Study 26866549 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlamydia testing intervention
Number of subjects: 13225
Study 25003812 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular clodronate 100mg/week (CLO) (N=36)
Number of subjects: 74
Study 25003812 — intervention group
Group type: COMPARATOR
Intervention: Yearly intravenous therapy with 5mg zoledronate (ZOL) (N=18)
Number of subjects: 74
Study 25003812 — intervention group
Group type: COMPARATOR
Intervention: Placebo (N=20)
Number of subjects: 74
Study 22534658 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion treatment
Number of subjects: 0
Study 19639726 — intervention group
Group type: EXPERIMENTAL
Intervention: Olopatadine (5 mg)
Number of subjects: 20
Study 19639726 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexofenadine (60 mg)
Number of subjects: 20
Study 19639726 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 17895350 — intervention group
Group type: EXPERIMENTAL
Intervention: Extension-oriented treatment approach (EOTA)
Number of subjects: 48
Study 17895350 — intervention group
Group type: COMPARATOR
Intervention: Strengthening exercise program
Number of subjects: 48
Study 15354104 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg aspirin
Number of subjects: 50
Study 15354104 — intervention group
Group type: EXPERIMENTAL
Intervention: 325 mg aspirin
Number of subjects: 50
Study 15354104 — intervention group
Group type: COMPARATOR
Intervention: 75 mg clopidogrel
Number of subjects: 50
Study 15354104 — intervention group
Group type: COMPARATOR
Intervention: Comparison between aspirin and clopidogrel
Number of subjects: 50
Study 12495795 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel cognitive-behavioral treatment (CBT)
Number of subjects: 23
Study 12495795 — intervention group
Group type: COMPARATOR
Intervention: Increased counseling (Control)
Number of subjects: 23
Study 9718104 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive case management intervention
Number of subjects: 298
Study 8007616 — intervention group
Group type: EXPERIMENTAL
Intervention: Subfascial lymphovenous anastomoses (LVA) operation combined with fenestration of the leg fascia
Number of subjects: 62
Study 8007616 — intervention group
Group type: COMPARATOR
Intervention: Epifascial LVA operation on the dorsal surface of the foot (Control group)
Number of subjects: 62